Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids

被引：0
|
作者：
Talaulikar, Vikram Sinai [1 ]
Manyonda, Isaac [1 ]
机构：
[1] St Georges Hosp & Univ London, London SW17 0RE, England
来源：
WOMENS HEALTH | 2014年 / 10卷 / 06期
关键词：
fibroids; medical; myoma; SPRM; ulipristal acetate;
D O I：
10.2217/WHE.14.60
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.
引用
收藏
页码：565 / 570
页数：6
相关论文
共 50 条
  • [41] Long-term medical management of uterine fibroids with ulipristal acetate
    Donnez, Jacques
    Donnez, Olivier
    Matule, Dace
    Ahrendt, Hans-Joachim
    Hudecek, Robert
    Zatik, Janos
    Kasilovskiene, Zaneta
    Dumitrascu, Mihai Cristian
    Fernandez, Herve
    Barlow, David H.
    Bouchard, Philippe
    Fauser, Bart C. J. M.
    Bestel, Elke
    Loumaye, Ernest
    FERTILITY AND STERILITY, 2016, 105 (01) : 165 - +
  • [42] Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids
    Middelkoop, Mei-An
    de Lange, Maria E.
    Clark, T. Justin
    Mol, Ben Willem J.
    Bet, Pierre M.
    Huirne, Judith A. F.
    Hehenkamp, Wouter J. K.
    HUMAN REPRODUCTION, 2022, 37 (05) : 884 - 894
  • [43] Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids
    Vikram S. Talaulikar
    Isaac T. Manyonda
    Advances in Therapy, 2012, 29 : 655 - 663
  • [44] Ulipristal Acetate Reverses Impaired Autophagy in Human Uterine Fibroids.
    Atabiekov, Ihor
    Al-Hendy, Ayman
    Ismail, Nahed
    El Andaloussi, Abdeljabar
    REPRODUCTIVE SCIENCES, 2018, 25 : 62A - 62A
  • [45] Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
    Bourdet, Alice Trefoux
    Luton, Dominique
    Koskas, Martin
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 321 - 330
  • [46] Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review
    Odejinmi, Funlayo
    Mallick, Rebecca
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2019, 41 (01) : 13 - 13
  • [47] Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis
    Kalampokas, Theodoros
    Kamath, Mohan
    Boutas, Ioannis
    Kalampokas, Emmanouil
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (02) : 91 - 96
  • [48] ULIPRISTAL ACETATE FOR UTERINE FIBROID-RELATED SYMPTOMS
    Puchar, A.
    Luton, D.
    Koskas, M.
    DRUGS OF TODAY, 2015, 51 (11) : 661 - 667
  • [49] Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate
    Yun, Bo Seong
    Seong, Seok Ju
    Jung, Yong Wook
    Kim, Mi-La
    Bae, Hyo Sook
    Kim, Mi Kyoung
    Shim, Sung Shin
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 224 : 133 - 136
  • [50] Uterine fibroids: NICE recommends new treatment option for moderate to severe symptoms
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 386
12345